Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis

AKDOĞAN N., DOĞAN GÜNAYDIN S., BOSTAN E., GÜLSEREN BÜYÜKDOĞAN D., YALICI ARMAĞAN B., ELÇİN G., ...Daha Fazla

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, cilt.14, sa.12, ss.1535-1541, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 12
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1080/17512433.2021.1979394
  • Dergi Adı: EXPERT REVIEW OF CLINICAL PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1535-1541
  • Anahtar Kelimeler: Psoriasis, therapy-systemic, switching, biologics, drug survival, BRITISH ASSOCIATION, DRUG SURVIVAL
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background The demand of biologic switching is increasing for different reasons.We aimed to define reasons for switching biologics and possible predictors for switching risk,and to estimate data on drug survival. Methods 115 patients treated with biologics who switched to a second, third,and/or fourth biologic were eligible for this retrospective study.Patients were divided into 2 groups as switched once,and switched twice or more.Drug survival rates were calculated using the Kaplan-Meier method. Results All patients switched at least one, 36 patients switched twice, and 9 switched thrice. First-, second-, and third-line biologics were mostly switched due to secondary lack of efficacy for skin disease.Each unit increase in age decreased the risk of having >= 2 switches 4% (p=0.038,OR:0.964,95%CI:0.93-0.998),whereas PsA increased the risk of having >= 2 switches 2.69-fold (p=0.026,OR:2.69,95%CI:1.12-6.44).There was significant difference between biologics in terms of drug survival(p=0.001).Adalimumab had a lower drug survival compared to ustekinumab(p<0.001) and secukinumab(p=0.003) in transition from second-line biologic to third-line biologic. Conclusion Switching biologics was most commonly due to secondary lack of efficacy for skin disease.Lower ages and the presence of PsA were associated with a higher need for switching in long-term.Ustekinumab and secukinumab are superior to adalimumab in clinical practice in terms of drug survival of second-line biologics